Exercise Training and Insulin Sensitivity

Sponsor
University of Missouri-Columbia (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05930834
Collaborator
(none)
24
1
1
16
1.5

Study Details

Study Description

Brief Summary

Regular exercise participation is known to reduce cardiometabolic disease risk but the impact that exercise training has on adipose tissue (AT) metabolism is poorly understood, particularly in humans. It is well established that exercise training improves whole-body glucose levels and increases insulin sensitivity, and this can occur within one or two weeks. These effects are usually due to adaptations in skeletal muscle, the tissue responsible for the majority of glucose disposal. However, many studies have now determined that exercise training also results in adaptations in AT that improve whole-body metabolic health by improving glucose uptake into the AT.

Skeletal muscle is thought to account for approximately 75-85% of glucose uptake , and this process is impaired in .individuals who are insulin-resistant state. It is postulated that the increased level of adiposity that accompanies severe obesity would result in higher dependency on AT for glucose uptake as the AT would be a bigger "sink". Thus the role of AT in inducing whole body insulin resistance is still unclear, particularly in individuals with obesity.

This study will examine the changes in AT glucose uptake before and after 4 weeks of exercise training in obese individuals and establish if there are sex differences.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: exercise
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
24 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Exercise Training and Adipose Tissue Insulin Sensitivity
Anticipated Study Start Date :
Aug 1, 2023
Anticipated Primary Completion Date :
Sep 1, 2023
Anticipated Study Completion Date :
Dec 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: Exercise

All subjects will undergo exercise training for 4 wks. 45-60 min of exercise, 4 sessions/wk supervised, 1 session unsupervised. intensity 60% of VO2 max

Behavioral: exercise
All subjects will undergo exercise training for 4 wks. 45-60 min of exercise, 4 sessions/wk supervised, 1 session unsupervised. intensity 60% of VO2 max

Outcome Measures

Primary Outcome Measures

  1. GLUT4 protein expression [4 weeks]

    protein expression

  2. TB1CD4 protein expression [4 weeks]

    TB1CD4 protein expression

Secondary Outcome Measures

  1. percent body fat [4 weeks]

    Body fat will be measured using DEXA pre and post training

Eligibility Criteria

Criteria

Ages Eligible for Study:
21 Years to 45 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • non-smokers, weight stable (<4 kg) within the last 6 months will be recruited for this study.

  • sedentary (not engaged in planned physical activities and performing less than a total of 2 h of physical activity per week during the last 6 months) men and women whose BMI is classified as obese (>30 kg/m2).

Exclusion Criteria:
  • cardiovascular disease, uncontrolled hypertension (no beta blockers), smokers, pregnant, have any recent changes in hormonal birth control, or on any medications known to impact metabolism.

  • All participants will be regular sleepers with a duration of 7-9 hours/night.

  • Subjects with orthopedic limitations will not be included.

Contacts and Locations

Locations

Site City State Country Postal Code
1 University of Misouri Columbia Missouri United States 65211

Sponsors and Collaborators

  • University of Missouri-Columbia

Investigators

  • Principal Investigator: Jill Kanaley, University of Missouri-Columbia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Jill Kanaley, Professor and Interim Chair, Nutrition and Exercise Physiology, University of Missouri-Columbia
ClinicalTrials.gov Identifier:
NCT05930834
Other Study ID Numbers:
  • 2096068
First Posted:
Jul 5, 2023
Last Update Posted:
Jul 5, 2023
Last Verified:
Jul 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jul 5, 2023